Namir Hassan

Company: Zelluna Immunotherapy

Job title: CEO

Seminars:

TCR-NK: A Unique Approach to Allogeneic Off the Shelf Cell Therapy Treatment of Solid Cancers 2:30 pm

The TCR-NK platform: bringing the solid tumor targeting benefits of TCRs and the highly potent off-the shelf killing mechanism of NK cells Developing a pipeline of TCR-NK products against well-validated TCR antigensRead more

day: Day One

Industry Leaders Fireside Chat – What Does the Future Hold for TCR therapies? 10:30 am

The hotly anticipated Industry Leader’s Fireside Chat will discuss the huge progress being made in the TCR therapeutic space. This session will explore the lessons we can takes from CAR-T, and will shed clarity on the priorities of the trailblazing companies in this field, whilst also touching upon the challenges faced with manufacturing costs, and…Read more

day: Day One